1 out of 5 children also have obesity

2-9 They do this by: Building confidence and self-efficacy by empowering patients to actively engage with their treatment journey Educating patients to address the widespread misconception that obesity is not a disease, with 40% of patients unaware of this and 80% feeling solely responsible for their condition Implementing a whole-health approach to redefine treatment success, focus on overall health outcomes, not just weight loss Setting realistic expectations which prepares patients for the possibility of losing less weight than expected while still achieving significant health benefits Supporting medication adherence by providing tools for reminders, routines, titration guidance, and addressing injection anxiety Driving medication persistence as a result of setting realistic expectations and frame treatment around long-term health gains rather than short-term weight loss Mitigating side effects through equipping patients to self-manage common side effects through proactive tracking and helping them connect the dots Want to learn even more about how digital solutions can unlock the full potential of GLP-1 therapies

Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
Doses above 2ml per injection do not produce additional fat loss because methylation pathways become saturated, and excess methionine converts to homocysteine rather than contributing to lipid metabolism
By delivering a highly absorbable form of setria glutathione , liposomal formulations can successfully penetrate the cellular membrane and replenish the mitochondrial antioxidant pools
Food and Drug Administration (FDA) approved for the stepwise treatment of T2DM